Enanta Pharmaceuticals began the first human dosing of its lead immunology candidate, EDP‑978, a once‑daily KIT inhibitor, on April 13 2026. The dose was administered to a healthy adult volunteer as part of a Phase 1 study that marks the transition of the drug from preclinical research into clinical evaluation.
The study is a single‑ascending‑dose (SAD) and multiple‑ascending‑dose (MAD) design that will enroll roughly 98 participants. It will assess safety, tolerability, pharmacokinetics and pharmacodynamics, and will measure serum tryptase levels to confirm target engagement and provide early pharmacodynamic signals.
Chief Medical Officer Scott T. Rottinghaus said the company is excited to move its lead immunology program into clinical development. He noted that chronic urticaria and other mast‑cell–driven diseases cause significant quality‑of‑life impairment, and that many patients are refractory to existing therapies, creating an unmet need for a new oral agent.
The initiation of the Phase 1 trial is a key milestone for Enanta’s immunology platform and sets the stage for an IND filing and subsequent Phase 2 studies. The company had selected EDP‑978 as its clinical candidate in November 2025 and was on track to submit an IND in the first quarter of 2026, positioning the drug for a potential market entry if later‑stage data are favorable.
Investors responded positively to the announcement, reflecting confidence in Enanta’s strategy to address a sizable unmet medical need in chronic urticaria and related mast‑cell disorders.
Other oral KIT inhibitors are being developed by competitors such as Blueprint Medicines, underscoring the competitive landscape. Chronic urticaria is a mast‑cell driven skin disorder that persists for six weeks or longer, and the lack of effective oral options highlights the therapeutic opportunity that EDP‑978 seeks to fill.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.